Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations

Br J Dermatol. 2017 Aug;177(2):587-590. doi: 10.1111/bjd.15463. Epub 2017 Jul 3.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter

MeSH terms

  • Analysis of Variance
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Dermatologic Agents / administration & dosage*
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Etanercept / administration & dosage*
  • Humans
  • Patient Reported Outcome Measures
  • Psoriasis / drug therapy*
  • Quality of Life
  • Risk Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • ixekizumab
  • Etanercept